Long-term outcomes for adults with lupus at Peking University People's Hospital
A Prospective Cohort Study on Long-Term Outcomes in Patients With Systemic Lupus Erythematosus at Peking University People's Hospital
This project will follow adults with lupus at Peking University People's Hospital for up to 10 years to see how disease activity, organ involvement, achievement of Lupus Low Disease Activity State (LLDAS), and survival change over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07005479 on ClinicalTrials.gov |
What this trial studies
This single-center, prospective observational cohort will enroll adults with SLE at Peking University People's Hospital and follow them for up to ten years. Regular visits will collect clinical assessments, laboratory tests, treatment histories, and patient-reported quality-of-life measures. Disease activity will be tracked using SLEDAI-2K and the study will record the frequency, duration, and determinants of achieving and maintaining Lupus Low Disease Activity State (LLDAS). Analyses will link LLDAS status, organ involvement, flare rates, treatments, and other factors with long-term survival and damage accrual in a Chinese patient population.
Who should consider this trial
Good fit: Adults (age 18 or older) diagnosed with SLE by ACR, SLICC, or EULAR/ACR criteria who can provide written consent are ideal candidates.
Not a fit: Children under 18, people unable to provide informed consent, and patients seeking immediate experimental therapies are unlikely to benefit directly from this observational follow-up.
Why it matters
Potential benefit: If successful, findings could help doctors personalize treatment plans by identifying patterns and predictors of long-term disease control and survival in Chinese patients with lupus.
How similar studies have performed: Prior long-term lupus cohorts have shown that reaching and maintaining LLDAS is associated with reduced damage accrual and better survival, so this study builds on validated findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients must meet at least one of the following classification criteria for Systemic Lupus Erythematosus (SLE): The 1997 American College of Rheumatology (ACR) Revised Classification Criteria; The 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria; The 2019 EULAR/ACR Classification Criteria for SLE. All patients must be over the age of 18 and competent to provide written consent. Exclusion Criteria: * Patients less than 18 years of age and patients who are unable to consent are excluded from the study.
Where this trial is running
Beijing, Beijing Municipality
- Department of Rheumatology and Immunology, Peking University People's Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Haihong Yao, MD
- Email: yaohaihong@pku.edu.cn
- Phone: 010-88326666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.